Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new review of previous studies into the long-term effects of childhood sexual abuse has suggested that earlier mental health support for victims would reduce the chances of victims developing psychiatric conditions and substance misuse later in life.

None © Shutterstock

Childhood sexual abuse is known to be associated with a wide range of health conditions, from chronic pain to mental health problems. There have been many studies examining these links but these typically looked at one outcome in adulthood, and there has not been a synthesis examining the full breadth of international research evidence and its quality.

A new review of these previous studies led by Oxford University researchers, suggests that pre-emptive interventions for victims and survivors of childhood sexual abuse should be prioritised to reduce the chances of victims developing common psychiatric conditions and substance misuse.

The researchers from the University’s Department of Psychiatry looked at quantitative reviews that used transparent and systematic searching strategies, also known as meta-analyses, of the research examining the chance of developing adult health conditions and psychosocial problems following childhood sexual abuse.

Read more (University of Oxford website)

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.